Bristol-Myers Squibb Company [BMY] gain 9.83% so far this year. What now?

Bristol-Myers Squibb Company [NYSE: BMY] plunged by -$1.22 during the normal trading session on Monday and reaching a high of $69.41 during the day while it closed the day at $68.48. The company report on October 7, 2022 that Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Bristol Myers Squibb (NYSE:BMY) announced that it has changed the dial-in and replay information of its previously announced third quarter 2022 earnings conference call scheduled for Wednesday, October 26, 2022. Company executives will review financial results and address inquiries from investors and analysts during a conference call at 8:00 a.m. ET that same day.

Bristol-Myers Squibb Company stock has also loss -2.91% of its value over the past 7 days. However, BMY stock has declined by -8.71% in the 3 months of the year. Over the past six months meanwhile, it has lost -11.95% and gained 9.83% year-on date.

The market cap for BMY stock reached $147.36 billion, with 2.14 billion shares outstanding and 2.13 billion shares in the current float. Compared to the average trading volume of 9.53M shares, BMY reached a trading volume of 8878696 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Bristol-Myers Squibb Company [BMY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $81.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 10, 2022. While these analysts kept the previous recommendation, Berenberg dropped their target price from $82 to $76. The new note on the price target was released on September 14, 2022, representing the official price target for Bristol-Myers Squibb Company stock.

The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.55, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.13. The Price to Book ratio for the last quarter was 4.48, with the Price to Cash per share for the same quarter was set at 6.17. Price to Free Cash Flow for BMY in the course of the last twelve months was 15.10 with Quick ratio for the last quarter at 1.30.

BMY stock trade performance evaluation

Bristol-Myers Squibb Company [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.91. With this latest performance, BMY shares dropped by -2.39% in over the last four-week period, additionally sinking by -11.95% over the last 6 months – not to mention a rise of 19.59% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 39.22, with the RSI for the last a single of trading hit 34.29, and the three-weeks RSI is set at 41.40 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 71.49, while it was recorded at 70.22 for the last single week of trading, and 71.61 for the last 200 days.

Bristol-Myers Squibb Company [BMY]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +20.57 and a Gross Margin at +57.69. Bristol-Myers Squibb Company’s Net Margin is presently recorded at +15.08.

Return on Equity for this stock inclined to 18.96, with Return on Assets sitting at 6.14.

Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.

Earnings per share (EPS) analysis for Bristol-Myers Squibb Company [BMY] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 4.65%.

Bristol-Myers Squibb Company [BMY]: Insider Ownership positions

There are presently around $113,499 million, or 79.70% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 196,828,094, which is approximately -0.837% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 170,645,262 shares of the stock with an approximate value of $11.69 billion in BMY stocks shares; and JPMORGAN CHASE & CO, currently with $6.69 billion in BMY stock with ownership of nearly 4.129% of the company’s market capitalization.

Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,120 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 117,375,077 shares. Additionally, 1,159 investors decreased positions by around 89,923,832 shares, while 347 investors held positions by with 1,450,104,903 shares. The mentioned changes placed institutional holdings at 1,657,403,812 shares, according to the latest SEC report filing. BMY stock had 150 new institutional investments in for a total of 8,953,430 shares, while 92 institutional investors sold positions of 8,195,659 shares during the same period.


Please enter your comment!
Please enter your name here